Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Enzalutamide

Catalog No: tcsc0317

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Size: 1g

Size: 2g

Size: 5g

Specifications

CAS No:
915087-33-1

Formula:
$C_{21}H_{16}F_4N_4O_2S$

Pathway:
Others;Autophagy

Target:
Androgen Receptor;Autophagy

Purity / Grade:
>98%

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Solubility:
DMSO : ≥ 50 mg/mL (107.66 mM); H2O :

Alternative Names:
MDV3100

Observed Molecular Weight:
464.44

Product Description

Enzalutamide is an **androgen-receptor (AR)** antagonist with **IC_{50}** of 36 nM in LNCaP cells.

IC50 & Target: IC50: 36 nM (androgen-receptor, in LNCaP cells)[1]

In Vitro: Enzalutamide has greater affinity to AR than Bicalutamide does in a competition assay with 16β-[^{18}F]fluoro-5α-DHT (18-FDHT) in castration-resistant LNCaP/AR cells (AR-overexpressing). While Enzalutamide shows no agonism in LNCaP/AR prostate cells. Enzalutamide antagonizes induction of prostate-specific antigen (PSA) and transmembrane serine protease 2 (TMPRSS2), combination with the synthetic androgen R1881 in parental LNCaP cells. Enzalutamide inhibits the transcriptional activity of a mutant AR protein (W741C, mutation of Trp741 to Cys)[1]. Enzalutamide also prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex[2].

In Vivo: Enzalutamide induces great tumor regression in castrate male mice bearing LNCaP/AR xenografts at a dose of 10 mg/kg[1]. Enzalutamide shows dose-independent pharmacokinetics at intravenous and oral doses of 0.5-5 mg/kg[4].